Published in J Neurol on October 29, 2008
Natalizumab De-escalation With Interferon Beta-1b | NCT01144052
Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Prog Neurobiol (2010) 1.36
Longitudinal extensive transverse myelitis--it's not all neuromyelitis optica. Nat Rev Neurol (2011) 1.30
Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol (2009) 1.18
Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis. Clin Dev Immunol (2011) 1.18
Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat (2009) 1.12
Retracted Multiple sclerosis: the role of cytokines in pathogenesis and in therapies. Int J Mol Sci (2012) 1.11
Youth and environmental enrichment generate serum exosomes containing miR-219 that promote CNS myelination. Glia (2013) 1.05
beta2-integrins in demyelinating disease: not adhering to the paradigm. J Leukoc Biol (2009) 1.03
Disease-modifying agents in multiple sclerosis. Ann Indian Acad Neurol (2009) 0.95
Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis. AJNR Am J Neuroradiol (2015) 0.90
Multiple sclerosis treatment and infectious issues: update 2013. Clin Exp Immunol (2014) 0.90
Optimizing treatment success in multiple sclerosis. J Neurol (2015) 0.90
Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases? EPMA J (2013) 0.89
Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis. J Neuroinflammation (2012) 0.88
Treatment of multiple sclerosis: role of natalizumab. Neurol Sci (2009) 0.88
Exercise in multiple sclerosis -- an integral component of disease management. EPMA J (2011) 0.87
Symptomatology of MS: results from the German MS Registry. J Neurol (2009) 0.87
Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol (2016) 0.86
Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study. BMC Neurol (2011) 0.85
Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients. PLoS One (2015) 0.84
Exercise therapy and multiple sclerosis: a systematic review. J Neurol (2013) 0.84
Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain. PLoS One (2012) 0.84
Escalating immunotherapy of multiple sclerosis. Ther Adv Neurol Disord (2008) 0.84
A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis. Arch Med Sci (2010) 0.82
Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group. Wien Med Wochenschr (2012) 0.82
Development and pilot phase of a European MS register. J Neurol (2010) 0.81
What are exosomes and how can they be used in multiple sclerosis therapy? Expert Rev Neurother (2014) 0.79
Managing MS in a changing treatment landscape. J Neurol (2011) 0.79
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat (2013) 0.79
Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis. Neurohospitalist (2013) 0.78
Immune mediated diseases and immune modulation in the neurocritical care unit. Neurotherapeutics (2012) 0.78
Multidisciplinary rehabilitation and steroids in the management of multiple sclerosis relapses: a randomized controlled trial. Arch Med Sci (2015) 0.78
Neuroinflammatory imaging biomarkers: relevance to multiple sclerosis and its therapy. Neurotherapeutics (2013) 0.78
Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective? BMC Neurol (2011) 0.78
Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis. Core Evid (2011) 0.77
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat (2011) 0.77
Switching and escalating therapy in long-lasting multiple sclerosis: not always necessary. ISRN Neurol (2012) 0.77
Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis. J Inflamm Res (2010) 0.76
Efficacy of vision restoration therapy after optic neuritis (VISION study): study protocol for a randomized controlled trial. Trials (2012) 0.76
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine. Drug Des Devel Ther (2010) 0.75
Multiple sclerosis and pregnancy; What a neurologist may be asked for? Iran J Neurol (2014) 0.75
A steroid-induced bilateral avascular necrosis of the femoral head in an underage patient affected by multiple sclerosis. Clin Cases Miner Bone Metab (2015) 0.75
Anaplastic astrocytoma mimicking progressive multifocal leucoencephalopathy: a case report and review of the overlapping syndromes. BMC Cancer (2017) 0.75
Clinical trials in multiple sclerosis: current and future requirements - potential pitfalls. J Neurol (2008) 0.75
Effect of methylprednisolone on mammalian neuronal networks in vitro. Cell Mol Neurobiol (2014) 0.75
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature (1992) 7.20
Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med (2006) 7.18
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain (2002) 6.85
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med (2006) 6.25
A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2003) 5.77
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med (2003) 4.86
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet (2004) 3.95
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet (2002) 3.74
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology (2002) 3.73
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet (2002) 3.48
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet (2003) 3.21
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology (2006) 2.75
Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol (2005) 2.67
The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol (2005) 2.44
IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology (2006) 2.43
Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol (2005) 2.43
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A (2004) 2.37
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology (2006) 2.24
An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther (2003) 2.09
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology (2004) 2.04
New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology (2003) 2.04
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol (2008) 2.02
Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain (2007) 1.93
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology (2002) 1.86
A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler (2002) 1.86
Natalizumab and PML. Nat Neurosci (2005) 1.85
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol (2005) 1.85
Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology (2004) 1.73
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol (2007) 1.73
Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med (2008) 1.69
Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology (2005) 1.65
Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology (2007) 1.63
The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology (2005) 1.62
Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Neurology (2007) 1.62
A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler (2007) 1.61
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61
Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler (2006) 1.60
Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology (2004) 1.58
Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol (2002) 1.57
Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology (2005) 1.56
Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology (2003) 1.54
Multiple sclerosis diagnostic criteria: three years later. Mult Scler (2005) 1.53
Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J Neurol (2005) 1.50
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry (1997) 1.44
The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci U S A (2005) 1.44
Intravenous Immunoglobulins in MS. Int MS J (2005) 1.41
Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol (2004) 1.40
Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology (2005) 1.39
Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology (2005) 1.37
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol (2007) 1.36
Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology (2005) 1.34
Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest (2001) 1.32
Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry (2006) 1.31
Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler (2005) 1.21
Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci (2005) 1.20
Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology (2004) 1.19
Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol (2006) 1.17
Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler (2003) 1.16
Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology (2005) 1.14
Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler (2005) 1.11
Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol (2005) 1.10
Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol (2006) 1.08
Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry (2007) 1.07
Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology (2002) 1.06
Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol (2008) 1.05
Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology (1996) 1.03
Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol (2004) 0.99
EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol (2006) 0.97
Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology (2006) 0.97
Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry (2006) 0.96
Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2007) 0.96
Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol (2005) 0.95
Selective treatment of multiple sclerosis. N Engl J Med (2006) 0.95
Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol (2004) 0.95
Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet (2004) 0.94
IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology (2004) 0.94
A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler (2005) 0.94
Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology (2006) 0.91
Human demyelinating disease and the polyomavirus JCV. Mult Scler (2006) 0.91
Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs (2004) 0.90
Visual and motor evoked potentials in the course of multiple sclerosis. Brain (2001) 0.90
Mycophenolate mofetil and neurological diseases. Lupus (2005) 0.90
Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J Neurol (2006) 0.89
Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol (2004) 0.88
Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler (2005) 0.88
Escalating immunotherapy of multiple sclerosis--new aspects and practical application. J Neurol (2004) 0.88
Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol (2007) 0.87
Anti-adhesion therapies. Curr Opin Pharmacol (2005) 0.87
Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother (2005) 0.86
Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch Neurol (2005) 0.86
Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr (1984) 9.61
Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict (1992) 5.02
Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med (1970) 4.90
Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci U S A (1997) 4.70
Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis (1978) 4.00
Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med (2000) 3.84
Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest (1994) 3.58
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Botulinum toxin for palmar hyperhidrosis. Lancet (1997) 3.17
Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med (1999) 2.84
Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man. J Infect Dis (1970) 2.71
Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol (2005) 2.67
Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ (1971) 2.64
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology (2012) 2.60
Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol (1998) 2.47
The pathology of the joint tissues and its clinical relevance in prosthesis failure. Clin Orthop Relat Res (1976) 2.46
Disseminated fusarial infection in the immunocompromised host. Rev Infect Dis (1989) 2.46
Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol (1995) 2.34
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology (2008) 2.29
Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr (1990) 2.28
2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy. Lancet (1997) 2.28
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26
Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med (1977) 2.23
Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length. Pediatrics (1989) 2.21
Acetaminophen prophylaxis of adverse reactions following vaccination of infants with diphtheria-pertussis-tetanus toxoids-polio vaccine. Pediatr Infect Dis J (1987) 2.20
Identification of an epidemic strain of group C Neisseria meningitidis by bactericidal serotyping. J Infect Dis (1971) 2.17
Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest (1975) 2.16
Results from the 1995 National College Health Risk Behavior Survey. J Am Coll Health (1997) 2.13
A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord (2000) 2.12
A role for BDNF in mechanosensation. Nat Neurosci (1998) 2.08
Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology (2011) 2.07
[Fumaric acid as therapeutic agent for multiple sclerosis]. Nervenarzt (2014) 1.97
[Current therapy of multiple sclerosis--high-dose intravenous therapy with corticosteroids]. Nervenarzt (1992) 1.93
The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders. Ann Neurol (1993) 1.92
Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain (2001) 1.91
Myasthenia gravis: passive transfer from man to mouse. Science (1975) 1.90
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology (2002) 1.86
Impact of multiple sclerosis relapses on progression diminishes with time. Neurology (2009) 1.86
Etiology of acute childhood encephalitis at The Hospital for Sick Children, Toronto, 1994-1995. Clin Infect Dis (1998) 1.85
Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol (1998) 1.83
Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy. Neurology (2010) 1.80
Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler (2002) 1.80
Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2000) 1.77
NMO-IgG in the diagnosis of neuromyelitis optica. Neurology (2007) 1.77
Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult Scler (2001) 1.76
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology (2011) 1.75
Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology (2001) 1.74
Bidirectional growth of the E. coli chromosome. Nat New Biol (1973) 1.73
Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology (1999) 1.73
Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology (2008) 1.72
Survey of parents' attitudes to the recommended Haemophilus influenzae type b vaccine program. CMAJ (1987) 1.72
Defective propagation of signals generated by sympathetic nerve stimulation in the liver of connexin32-deficient mice. Proc Natl Acad Sci U S A (1996) 1.68
Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis (1979) 1.67
Prednisone in Duchenne muscular dystrophy. Lancet (1974) 1.65
TNFRSF1A R92Q mutation in association with a multiple sclerosis-like demyelinating syndrome. Neurology (2008) 1.63
Autoimmune human T lymphocytes specific for acetylcholine receptor. Nature (1984) 1.63
Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol (2006) 1.62
Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med (1990) 1.60
Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia. J Antimicrob Chemother (1983) 1.60
Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis. Ann Neurol (1998) 1.60
Linkage of proximal myotonic myopathy to chromosome 3q. Neurology (1999) 1.60
Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet (1995) 1.60
Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler (2006) 1.60
Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology (2005) 1.56
CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology (2012) 1.55
The correlation between ventricular diameter measured by transcranial sonography and clinical disability and cognitive dysfunction in patients with multiple sclerosis. Arch Neurol (2000) 1.55
Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci U S A (2000) 1.53
Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology (1983) 1.53
Early natural course of transient encephalopathy after coronary artery bypass grafting. Crit Care Med (2000) 1.52
Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler (2011) 1.51
Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics (1977) 1.50
[Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002]. Nervenarzt (2002) 1.50
Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am J Pathol (1993) 1.50
Neuromyotonia in mice with hereditary myelinopathies. Muscle Nerve (2000) 1.50
Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-alpha by HLA-DR2+ T cells. Ann Neurol (1995) 1.50
Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today (2000) 1.49
Superficial siderosis of the central nervous system: pathogenetic heterogeneity and therapeutic approaches. Acta Neurol Scand (2003) 1.49
Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve (2002) 1.47
Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain (2000) 1.47
CADASIL: underdiagnosed in psychiatric patients? Acta Psychiatr Scand (2005) 1.45
["Chronic cerebrospinal venous insufficiency" and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients]. Nervenarzt (2010) 1.45
[Pregnancy and immunomodulatory therapy in multiple sclerosis patients]. Nervenarzt (2006) 1.45
Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG--the ICE study. Eur J Neurol (2012) 1.45
IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun (2008) 1.43
A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases. Clin Orthop Relat Res (1985) 1.42
Intravenous Immunoglobulins in MS. Int MS J (2005) 1.41
Treating HIV encephalopathy with antiretroviral therapy: a clinical case demonstrating the success of HAART. Clin Infect Dis (2004) 1.41
Diversity of the anti-T-cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis. Brain (1998) 1.41
Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol (1998) 1.40
[Myopathies under therapy with lipid-lowering agents]. Nervenarzt (2005) 1.40